melan-A vaccine

Melan-A vaccine is a **nonproprietary, non-unique therapeutic melanoma vaccine descriptor** used for vaccine preparations containing a Melan-A/MART-1-derived peptide antigen. In the completed Phase 1 study NCT00324623, the product was described as a Melan-A vaccine emulsified in incomplete Freund's adjuvant and administered after lymphodepleting chemotherapy and autologous peripheral-blood mononuclear-cell reinfusion; a related publication characterizes the intervention as repeated vaccination with a MART-1 analog peptide, with or without the LAG-3Ig adjuvant IMP321. The intended mechanism is induction and expansion of Melan-A/MART-1-specific cytotoxic CD8-positive T-cell responses against melanoma cells expressing this differentiation antigen. The exact peptide sequence, analog, dose, and commercial product identity are not specified by the input name alone. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00324623))

Other names

Melan-A/MART-1 vaccineMART-1 peptide vaccineMART1 peptide vaccineMART 1 peptide vaccine